Introduction: Today, different nanostructures are used to deliver drugs for various diseases, including neurological diseases, because of their biodegradability and increase in drug efficiency, and reduction of side effects[1]. Experimental/Method: Chitosan-caseinate nanoparticles were synthesized by polyelectrolyte complex (PEC) formation. Caseinate is an anionic micellar nanocolloid in aqueous solutions, which association with the polycationic chitosan yielded polyelectrolyte complexes with caseinate cores surrounded by a chitosan corona[2]. The pre-structuration of caseinate micelles facilitates the formation of natural polyelectrolyte nanoparticles with good stability and sizes around 200 nm without drugs and around 300 nm when carrying durgs, and their effective antioxidant power was evaluated by the DPPH test. Attenuated total reflectionFourier transform infrared (ATR-FTIR) analyses revealed the chemical structure of hydrogel colloidal systems consisting of nanoparticles that contain chitosan and caseinate. Scanning electron microscope (SEM) allowed further characterization of the spherical morphology of the nanoparticles. Results and discussion: A combination of two drugs was chosen as a model drug to study the application of the nanoparticles as a safe biodegradable nanocarrier system for drugcontrolled release. Quercetin and syringic acid, which have effective antioxidant properties and are common in the medical industry[3-4], were tested in our experiments with different concentration ratios (1:2, 2:1, and 1:1) for transport by chitosan-Caseinate nanoparticles. The optimal concentration ratio (1:1) was selected for drug loading on the nanoparticles. The antioxidant power was evaluated by the DPPH test, results showed that the best antioxidant power (IC50) of the nanodrug was at the concentration of 15 g/ml of nanoparticles. Conclusion: This type of polymer-protein drug carrier for drug delivery is recommended for improve the performance of drugs, especiall
